Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
10 studies found for:    ugt1a1 | Open Studies | Interventional Studies | colorectal cancer | irinotecan

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer
Condition: First Line Metastatic Colorectal Cancer
Intervention: Drug: Irinotecan
2 Recruiting Prospective Analysis of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Combined With FOLFIRI as the First-line Setting
Condition: Metastatic Colorectal Cancer
Interventions: Genetic: UGT1A1 genotyping (6,6);   Genetic: UGTIA1 genotyping (6,7);   Genetic: UGTIA1 genotyping (7,7);   Genetic: UGT1A1 non-genotyping;   Drug: bevacizumab (Avastin);   Drug: irinotecan;   Drug: Leucovorin;   Drug: 5-FU
3 Unknown † Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Irinotecan high doses;   Drug: Irinotecan standard doses
4 Recruiting A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
Conditions: Colorectal Neoplasms;   Neoplasm Metastasis;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasms
Interventions: Biological: Bevacizumab;   Drug: CPT-11 (Irinotecan);   Drug: 5-FU Bolus;   Drug: 5-FU Infusion;   Drug: l-LV (dl-LV);   Biological: bevacizumab;   Drug: Capecitabine
5 Recruiting Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
Condition: Colon Cancer
Interventions: Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Irinotecan;   Drug: Bevacizumab
6 Unknown † Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
7 Recruiting Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases
Condition: Colorectal Cancer
Interventions: Drug: Cetuximab;   Drug: Bevacizumab;   Drug: Irinotecan;   Drug: Oxaliplatin;   Drug: 5-FU;   Drug: Folinic Acid
8 Recruiting FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: FOLFOXIRI;   Drug: FOLFOX
9 Recruiting Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI).
Condition: Colorectal Cancer Metastatic
Intervention: Device: DEBIRI
10 Recruiting Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma of Unknown Primary;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Diffuse Adenocarcinoma of the Stomach;   Duct Cell Adenocarcinoma of the Pancreas;   Intestinal Adenocarcinoma of the Stomach;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Carcinoma of Unknown Primary;   Metastatic Extrahepatic Bile Duct Cancer;   Mixed Adenocarcinoma of the Stomach;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Newly Diagnosed Carcinoma of Unknown Primary;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage III Pancreatic Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Rectal Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Colon Cancer;   Stage IVA Gallbladder Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Gallbladder Cancer;   Stage IVB Rectal Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis
To Top

† Indicates status has not been verified in more than two years